Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...
Drug Delivery Business

Analysts outline future catalysts for Dexcom with 15-Day CGM, potential reimbursement wins

BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.
Seeking Alpha

Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
Yahoo

The FDA Just Cleared the Dexcom G7 15-Day, the Longest-Lasting CGM

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Healio

FDA clears next-generation Dexcom 15-day CGM for adults with diabetes

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The Dexcom G7 15 Day ...
Hosted on MSN

The FDA Just Cleared the Dexcom G7 15-Day, the Longest-Lasting CGM Wearable

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...